Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

224 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Body habitus changes and metabolic alterations in protease inhibitor-naive HIV-1-infected patients treated with two nucleoside reverse transcriptase inhibitors.
Galli M, Ridolfo AL, Adorni F, Gervasoni C, Ravasio L, Corsico L, Gianelli E, Piazza M, Vaccarezza M, d'Arminio Monforte A, Moroni M. Galli M, et al. Among authors: gervasoni c. J Acquir Immune Defic Syndr. 2002 Jan 1;29(1):21-31. doi: 10.1097/00126334-200201010-00003. J Acquir Immune Defic Syndr. 2002. PMID: 11782586
Viral interference between hepatitis B, C, and D viruses in dual and triple infections in HIV-positive patients.
Morsica G, Bagaglio S, Cicconi P, Capobianchi MR, Pellizzer G, Caramello P, Orani A, Moioli C, Rizzardini G, Uberti-Foppa C, Puoti M, Monforte AD; Hepa I.C.o.N.A the Icona Foundation Study Groups. Morsica G, et al. J Acquir Immune Defic Syndr. 2009 Aug 15;51(5):574-81. doi: 10.1097/QAI.0b013e3181add592. J Acquir Immune Defic Syndr. 2009. PMID: 19590432
Italian guidelines for the use of antiretroviral agents and the diagnostic-clinical management of HIV-1 infected persons. Update 2011.
Antinori A, Marcotullio S, Ammassari A, Andreoni M, Angarano G, Armignacco O, Carosi G, Cinque P, d'Arminio Monforte A, Di Perri G, Ensoli B, Floridia M, Galli M, Mastroianni C, Matteelli A, Mazzotta F, Moroni M, Pal G, Puoti M, Puro V, Rizzardini G, Sagnelli E, Vella S, Vullo V, Lazzarin A; Italian HIV Guidelines Working Group. Antinori A, et al. New Microbiol. 2012 Apr;35(2):113-59. Epub 2012 Mar 31. New Microbiol. 2012. PMID: 22707127 Free article. No abstract available.
Immune activation and microbial translocation in liver disease progression in HIV/hepatitis co-infected patients: results from the Icona Foundation study.
Marchetti G, Cozzi-Lepri A, Tincati C, Calcagno A, Ceccherini-Silberstein F, De Luca A, Antinori A, Castagna A, Puoti M, Monforte Ad; Icona Foundation Study Group. Marchetti G, et al. BMC Infect Dis. 2014 Feb 12;14:79. doi: 10.1186/1471-2334-14-79. BMC Infect Dis. 2014. PMID: 24520976 Free PMC article.
Comparison of the pharmacokinetics of raltegravir given at 2 doses of 400 mg by swallowing versus one dose of 800 mg by chewing in healthy volunteers: a randomized, open-label, 2-period, single-dose, crossover phase 1 study.
Cattaneo D, Cossu MV, Fucile S, Riva A, Baldelli S, Meraviglia P, Landonio S, Impagnatiello C, Resnati C, Galli M, Clementi E, Capetti A, Rizzardini G, Gervasoni C. Cattaneo D, et al. Among authors: gervasoni c. Ther Drug Monit. 2015 Feb;37(1):119-25. doi: 10.1097/FTD.0000000000000114. Ther Drug Monit. 2015. PMID: 24988438 Clinical Trial.
Prolonged inductive effect of rifampicin on linezolid exposure.
Gervasoni C, Simonetti FR, Resnati C, Charbe N, Clementi E, Cattaneo D. Gervasoni C, et al. Eur J Clin Pharmacol. 2015 May;71(5):643-4. doi: 10.1007/s00228-015-1833-z. Epub 2015 Mar 18. Eur J Clin Pharmacol. 2015. PMID: 25778934 No abstract available.
224 results